IOM Findings Strengthen Administrative Challenge to Repeal Marijuana's Prohibitive Status 3/26/99

Drug War Chronicle, recent top items


recent blog posts "In the Trenches" activist feed


(reprinted from the NORML Weekly News,

March 23, 1999, New York, NY: Determinations released last week by the Institute of Medicine that marijuana holds medical value and has a low potential for abuse supports an administrative petition that seeks to remove marijuana's classification as a Schedule I prohibited drug.

Petitioners Jon Gettman, former NORML National Director, and Trans High Corporation, publisher of High Times Magazine, announced last week that the IOM findings back their administrative effort to reclassify marijuana. "The IOM findings support [our] petition to the DEA demanding the reclassification of marijuana from a Schedule I drug like cocaine and heroin to a lower classification consistent with its therapeutic potential and relative harmlessness," said NORML Legal Committee member Michael Kennedy, attorney for the petitioners.

By definition, all Schedule I drugs must have a "high potential for abuse" and "no currently accepted medical use in treatment." In contrast, the IOM report found that "few marijuana users develop dependence," and called the drug's withdrawal symptoms "mild and short-lived." IOM researchers further determined that there is no evidence marijuana acts as a gateway to harder drug use, and summarized, "Except for the harms associated with smoking, the adverse effects of marijuana use are within the range of effects tolerated for other medications."

Gettman and Trans High Corporation filed an administrative petition with the Drug Enforcement Administration in 1995, arguing that marijuana lacks the requirements necessary for classification as a Schedule I or Schedule II drug. Last year, the DEA requested the Department of Health and Human Services (HHS) to conduct a "scientific and medical valuation of the available data and provide a scheduling recommendation" for marijuana and other cannabinoid drugs. That recommendation is still pending.

-- END --
Link to Drug War Facts
Please make a generous donation to support Drug War Chronicle in 2007!          

PERMISSION to reprint or redistribute any or all of the contents of Drug War Chronicle (formerly The Week Online with DRCNet is hereby granted. We ask that any use of these materials include proper credit and, where appropriate, a link to one or more of our web sites. If your publication customarily pays for publication, DRCNet requests checks payable to the organization. If your publication does not pay for materials, you are free to use the materials gratis. In all cases, we request notification for our records, including physical copies where material has appeared in print. Contact: the Drug Reform Coordination Network, P.O. Box 18402, Washington, DC 20036, (202) 293-8340 (voice), (202) 293-8344 (fax), e-mail [email protected]. Thank you.

Articles of a purely educational nature in Drug War Chronicle appear courtesy of the DRCNet Foundation, unless otherwise noted.

Issue #84, 3/26/99 Announcements | New Report Finds One Million Americans Incarcerated for Non-Violent Offenses | IOM Findings Strengthen Administrative Challenge to Repeal Marijuana's Prohibitive Status | Alert: Support California Syringe Decriminalization Bill | American Pharmaceutical Association Adopts Syringe Deregulation Position | Vancouver Needle Exchange Study Clarifies Previous Study's Results | Newsbriefs | Editorial: Rolling Back the Tide
Mail this article to a friend
Send us feedback on this article
This issue -- main page
This issue -- single-file printer version
Drug War Chronicle -- main page
Chronicle archives
Subscribe now!
Out from the Shadows HEA Drug Provision Drug War Chronicle Perry Fund DRCNet en EspaŮol Speakeasy Blogs About Us Home
Why Legalization? NJ Racial Profiling Archive Subscribe Donate DRCNet em PortuguÍs Latest News Drug Library Search
special friends links: SSDP - Flex Your Rights - IAL - Drug War Facts the Drug Reform Coordination Network (DRCNet)
1623 Connecticut Ave., NW, 3rd Floor, Washington DC 20009 Phone (202) 293-8340 Fax (202) 293-8344 [email protected]